Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to
decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis
and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is
extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal
tract, respiratory and genitourinary systems.